Similarly, after random matching by age and sex, MS, low-risk, and high-risk populations (148 individuals in each group), the prevalence of SARS-CoV-2 IgG/IgM in MS (n = 6, 4.0%) was significantly lower than in the high-risk population (n = 20, 13.5%) (p = 0.001) and similar to the low-risk population (n = 1, 0.7%) (p = 0.130). The gene discussed is CD40LG; the disease is myeloid sarcoma.